Carvedilol Hexal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carvedilol Hexal

Property Description
Active ingredient Carvedilol (a racemic mixture)
Form Tablet, film-coated tablets, extended-release capsules
Pharmacological class Beta-blocker with Alpha-1 Adrenergic Antagonist properties
Common use Cardiovascular conditions (e.g., managing high blood pressure)
Origin Synthetic (chemically synthesized)

What Type of Medicine is Carvedilol and How Does it Work Generally?

Carvedilol Hexal is a prescription-only, synthetic cardiovascular medicine whose active ingredient is Carvedilol. This compound is classified as a dual-acting nonselective beta-adrenergic and alpha1-adrenergic receptor antagonist, a feature recognized for supporting comprehensive circulatory system management.

Carvedilol's dual mechanism differentiates it from single-action beta-blockers by simultaneously targeting the heart and peripheral blood vessels. The medicine reduces the heart's workload while also promoting the relaxation and widening of the arteries. This combination of effects effectively lowers blood pressure and heart rate. This fundamental action helps to stabilize the mechanical function of the cardiovascular system by improving circulation and reducing resistance.

Carvedilol Hexal: Composition and Pharmaceutical Form

The medicine is supplied for oral administration, typically formulated as tablets or film-coated tablets, though extended-release forms are also available. Carvedilol is a chemically synthesized entity of entirely synthetic origin, not derived from natural sources.

As a single-ingredient product, the active agent, Carvedilol, is a racemic mixture where both the R(+) and S(-) enantiomers contribute to the overall therapeutic effect. The active component is combined with solid pharmaceutical excipients to create the final dosage form. The Hexal brand designation focuses on providing this established single-entity formulation to adult patient groups requiring long-term cardiovascular support.

What side effects are possible with Carvedilol Hexal?

Possible side effects and safety information

Official regulatory documents classify the safety profile of Carvedilol based on the frequency and the physiological system affected, providing a descriptive overview of documented risks. Adverse effects are most frequently observed in the Cardiovascular, Nervous System, and Metabolic domains.

Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions, classified as Very Common (ge 1/10) in regulatory documents, are dizziness and fatigue. Reactions listed as Common (ge 1/100 to < 1/10) include bradycardia (slow heart rate), hypotension (low blood pressure), headache, weight increase, and gastrointestinal disturbances such as nausea or diarrhea.

Less frequent events (Uncommon to Very Rare) include syncope, depression, sleep disturbances, and serious, though rare, events like severe cutaneous reactions (e.g., Stevens-Johnson Syndrome).

System-Organ Class (SOC) Focus Documented Effects
Cardiovascular Bradycardia, hypotension, aggravation of heart failure
Nervous System Dizziness, headache, syncope, paresthesia
Metabolic Weight increase, hyperglycemia (elevated blood sugar)

Population-Specific Safety Considerations

The official labeling mandates specific safety considerations for certain patient groups. The medicine is contraindicated in severe hepatic impairment. For patients with existing coronary artery disease, abrupt discontinuation is documented to carry a risk of exacerbation of angina pectoris or, rarely, myocardial infarction, necessitating a gradual reduction.

Dizziness and hypotension are documented as transient effects often more pronounced during the initiation of treatment or following dose adjustments. Serious adverse reactions documented in regulatory sources include the aggravation of heart failure and renal function deterioration in specific at-risk patients.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Carvedilol Hexal is associated with documented manifestations of severe physiological depression, primarily affecting the cardiovascular system due to excessive blockade of adrenergic receptors.

Officially Documented Manifestations and Severe Outcomes

Regulatory authorities state that an overdose may present with signs of profound hemodynamic depression. These manifestations include severe hypotension, a marked bradycardia (slow heartbeat), and acute cardiac insufficiency. Other documented signs can involve bronchospasms, frequent vomiting, lapses of consciousness, and the potential for generalized seizures (convulsions).

The most serious, life-threatening outcomes described in regulatory documents are cardiogenic shock, cardiac arrest, and acute respiratory failure.

Required Emergency Actions and Management

Immediate medical help must be sought if an overdose is suspected. Government guidance emphasizes that you must seek emergency medical attention or call emergency services immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management is officially defined as symptomatic and supportive. Regulatory information indicates that no specific antidote is known for Carvedilol overdose. Procedures may include gastric decontamination (such as gastric lavage and activated charcoal) if the massive ingestion was recent, and the use of pharmacological agents like Atropine and Glucagon for severe cardiac depression. Monitoring of the patient's condition must be prolonged due to the drug's properties.

Therapeutic Uses of Carvedilol Hexal

Carvedilol Hexal is used exclusively for the long-term management of specific, serious cardiovascular conditions, providing support for stability and functional support to the heart and circulatory system. It is applied across therapeutic domains where additional symptomatic support is needed. The therapeutic focus is on easing symptoms that create noticeable physiological strain.


Key Therapeutic Domains

The medication is commonly used across conditions presenting with systemic high blood pressure (hypertension) and in conditions involving episodic or fluctuating manifestations like chronic heart failure (CHF) and post-heart attack heart muscle changes. This application helps address symptom clusters that may become intense or disruptive.

“It helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.”

In chronic heart failure, it helps support the patient during the symptomatic phase by easing distress and maintaining functional stability, which is relevant for patients managing mild to severe chronic disease. For hypertension, it is relevant for easing the underlying symptom cluster of heightened physiological activity, which helps reduce symptoms related to systemic imbalance. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Cardiovascular Strain

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Status

Official regulatory documents define the eligibility for Carvedilol Hexal based on specific, high-risk pre-existing conditions that are designated as contraindications (absolute exclusions).

Classification Restricted Populations
Contraindicated Individuals with severe hepatic impairment (severe liver disease), bronchial asthma or related bronchospastic conditions, severe bradycardia (slow heart rate, unless a permanent pacemaker is present), second- or third-degree atrioventricular (AV) block, or sick sinus syndrome (unless a permanent pacemaker is present).
Contraindicated Patients in cardiogenic shock or decompensated heart failure requiring intravenous inotropic support, and those with a history of serious hypersensitivity reaction to carvedilol or its components.
Use Not Established Children and adolescents (under 18 years of age); safety and efficacy have not been established in the pediatric population.

Carvedilol Hexal is generally permitted for adult patients who are clinically stable and do not possess any of the documented contraindications. Use during pregnancy is typically restricted to instances where the potential benefit is judged to outweigh the potential risk to the fetus. It is unknown if the drug is excreted in human milk, leading to the recommendation to avoid breastfeeding or discontinue the medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents interactions between Carvedilol and other medicines primarily through pharmacokinetic and pharmacodynamic mechanisms, resulting in specific administration constraints.

Pharmacokinetic Interactions (Exposure Modification)

Co-administration with certain medicines alters Carvedilol’s plasma concentration (exposure). Strong enzyme inducers like Rifampin are documented to decrease Carvedilol exposure ( AUC and C max) by approximately mathbf70%. Conversely, CYP2D6 inhibitors, including Fluoxetine and Paroxetine, or Cimetidine, may increase Carvedilol plasma levels. Additionally, Carvedilol has been shown to increase the plasma concentration of Cyclosporine due to its effect on drug transporters.

Pharmacodynamic Interactions and Administration Rules

Additive effects are documented with several medicine classes. Co-administration with Digitalis Glycosides (e.g., Digoxin) or Calcium-Channel Blocking Agents (e.g., Verapamil, Diltiazem) carries an official risk of mathbfadditive negative effects on heart rate and AV conduction, potentially leading to bradycardia. Similarly, co-use with Hypotensive Agents or Amiodarone may increase the risk of severe mathbfhypotension.

Official labeling includes mandatory timing constraints: Immediate-release Carvedilol tablets must be taken with food to manage the rate of absorption. Furthermore, consumption of alcohol must be avoided within 2 hours before or after taking the extended-release capsule to prevent rapid drug release. Use in patients with mathbfsevere hepatic impairment is formally contraindicated due to expected reduced clearance.

Mechanism of Action

The mechanism of Carvedilol is defined by its dual blockade of adrenergic receptors. It acts as a competitive antagonist at non-selective beta (beta1 and beta2) receptors and selective alpha-1 (alpha1) receptors, preventing the binding of endogenous catecholamines like norepinephrine.

The beta1 receptor blockade in the myocardium reduces the force and rate of contraction, resulting in decreased cardiac output and lowered myocardial oxygen consumption. Simultaneously, alpha1 receptor blockade in peripheral vasculature prevents vasoconstriction, resulting in peripheral vasodilation and reduced systemic vascular resistance. This balanced hemodynamic modulation, achieved by the synergistic reduction of both cardiac output and peripheral resistance, characterizes the drug's primary action.

Beyond receptor antagonism, the drug influences feedback regulation within the Renin-Angiotensin-Aldosterone System (RAAS) by inhibiting renin release. Carvedilol also possesses non-receptor-mediated antioxidant properties, acting as a scavenger of free radicals, which contributes to cellular defense pathways.

Dosage and Administration Information

How to Use Carvedilol Hexal: Administration Guidelines

Carvedilol Hexal, containing the active ingredient carvedilol, is intended for oral administration only. The use of this medicine is characterized by a precise administration schedule and a required dose-escalation process, which is critical for proper use.


Administration Scope

Property Description
Route of administration Oral administration only.
Dosing schedule Therapy begins at a low starting dose, such as 3.125 mg twice daily for heart failure, followed by gradual, step-wise titration. Doses are only increased after intervals of at least two weeks, based on tolerability.
Timing in relation to meals All formulations must be taken with food to minimize the risk of orthostatic effects.
Preparation requirements Extended-release capsules must be swallowed whole and should not be chewed or crushed. Some immediate-release tablets, however, may be scored and divided for titration purposes.
Age-group administration rules For older adults with hypertension, some regimens suggest initiating therapy with a lower once-daily dose of 12.5 mg (IR form).
Missed-dose rules If treatment is interrupted for more than two weeks, the protocol requires the dose to be restarted at the lowest initial dose and re-titrated.

Connection to the Use Protocol

Standard instructions mandate a specific procedural structure for use. The food requirement is a fixed condition for proper daily intake. The titration schedule ensures that the dose is increased incrementally over extended intervals, moving from the lowest starting dose to the necessary maintenance level only as tolerated. This procedural structure is designed to adhere to the standardized use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence in Acute Pain Management

Research has examined the combination's effect on pain scores in both acute and chronic settings. Studies have evaluated the drug's role in post-surgical recovery and acute injury settings.

  • Some studies examined the initial time point at which the combination showed differences from placebo in acute pain settings.
  • The primary endpoint in most acute trials was the assessment of pain scores (e.g., VAS or NRS) within the first 24 hours of administration.
  • Research also documented specific findings when administered concurrently with other CNS depressants.

Evidence in Chronic Pain Management

In chronic pain, research investigated the change in pain scores over a 12-week period. The patient groups included those with chronic low back pain and neuropathic pain conditions.

  • Studies monitored safety and tolerability over periods of long-term management.
  • Secondary endpoints included changes in quality of life metrics and patient-reported functionality.
  • Studies also compared the combination to single-drug treatments in similar patient groups.

Study Focus on the Combination

Initial studies focused on the rationale for combining the two agents.

  • Pre-clinical evidence suggested that combining the two agents may affect the therapeutic window.

Subgroup Analysis and Safety Findings

Subgroup analyses investigated response rates based on age, sex, and baseline pain severity.

  • The data from the trials described the observed outcomes.
  • Studies in participants with existing liver conditions documented specific findings regarding safety parameters.
  • Commonly reported side effects included nausea, dizziness, and somnolence.

Frequently Asked Questions (FAQ)

Common questions about Carvedilol Hexal (FAQ)

Q: Why do doctors prescribe Carvedilol Hexal for heart failure?

Official documents state Carvedilol is indicated for chronic heart failure. Its mechanism involves reducing the heart's workload and promoting the widening of blood vessels, which are actions described as supportive of cardiovascular function.


Q: How is Carvedilol Hexal different from other blood pressure medicines?

Carvedilol is categorized as a dual-acting medicine. It works as both a beta-blocker, which reduces the heart rate and output, and an alpha-1 antagonist, which relaxes blood vessels. This dual mechanism is the primary feature that distinguishes it from medications that only perform one of these actions.


Q: Does Carvedilol Hexal lower blood pressure right away?

While some blood pressure-lowering effects may be seen within minutes to an hour of taking the medicine, the full intended antihypertensive effect develops gradually. Official reference information suggests the complete effect may take approximately one to two weeks after initiation.


Q: How long does it usually take to feel the effects of Carvedilol Hexal?

Official patient education emphasizes that the full benefits of treatment, especially for long-term conditions like heart failure, may take three to six months to become fully apparent. Although blood pressure can change sooner, patients are often advised that the most significant improvements take several months of consistent use.


Q: What should I know about Carvedilol Hexal and diabetes?

Regulatory information indicates that Carvedilol may be associated with masking certain symptoms of low blood sugar, such as a rapid heartbeat. Furthermore, some patients with heart failure who also have diabetes may experience elevated blood sugar levels while taking this medicine.


Q: Does Carvedilol Hexal interact with common pain relievers like ibuprofen?

Official interaction sources note that non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering effect of Carvedilol. This effect is generally observed when NSAIDs are used frequently.


Q: Is it true that Carvedilol Hexal can cause weight gain for some people?

Yes, official safety profiles classify weight increase as a Common side effect, meaning it is documented to affect up to 1 in 10 users. This is a possibility noted in the regulatory documents.


Q: What happens if you stop taking Carvedilol Hexal suddenly?

For patients with coronary artery disease, official warnings state that abruptly stopping Carvedilol therapy carries a risk of worsening symptoms of angina or, rarely, causing a heart attack. Due to this documented risk, official guidelines describe a required protocol of gradual dose reduction.


Q: Why do some people take Carvedilol Hexal for anxiety or tremors?

Carvedilol is officially indicated only for cardiovascular conditions, such as heart failure, high blood pressure, and stable angina. It is not approved by regulatory bodies to treat anxiety or tremors.


Q: Can Carvedilol Hexal affect your sleep?

Yes, official safety information lists sleep disorders as an Uncommon side effect. This means it has been documented to affect up to 1 in 100 users.


Q: Does Carvedilol Hexal impact cholesterol levels?

Official studies indicate that Carvedilol may alter serum lipid profiles. This can include documented changes such as an increase in triglycerides or a decrease in HDL cholesterol, which is sometimes referred to as 'good cholesterol.'


Q: Is it true that Carvedilol Hexal is also used for stable angina?

Yes, regulatory documents, particularly in Europe, state that Carvedilol is indicated for the prophylactic, or preventive, treatment of stable angina pectoris, a condition that causes chest pain.


Q: What is the difference between a beta-blocker and an alpha-blocker?

A beta-blocker primarily works by reducing the heart rate and the amount of blood the heart pumps. An alpha-blocker primarily relaxes and widens the blood vessels. Carvedilol is distinct because it has a dual action, targeting both of these mechanisms simultaneously.


Q: What regulatory bodies have approved Carvedilol Hexal?

The active ingredient, carvedilol, has been approved by major regulatory bodies globally. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: Can this medication cause mood changes or depression?

Yes, official safety documents list depression or depressed mood as a Common side effect, meaning it is documented in up to 1 in 10 users.


Q: Does using alcohol with Carvedilol Hexal create a known risk?

Official interaction sources note that alcohol may have an additive effect with the medicine's blood pressure-lowering action. This could potentially increase the risk of dizziness or fainting.


Q: Does Carvedilol Hexal affect kidney function?

Regulatory labeling notes a documented potential for renal function abnormalities. This is of particular concern for at-risk patients, such as those with pre-existing vascular disease or kidney problems.


Q: Can Carvedilol Hexal cause dry mouth?

Dry mouth has been documented in some official safety profiles as a Rare side effect. This means it is a possibility, though one that affects very few users.


Q: What kind of monitoring does the FDA/EMA recommend for patients on Carvedilol Hexal?

Official guidelines recommend monitoring for several factors, including heart rate, blood pressure, blood sugar (for diabetic patients), and weight gain, particularly during the initial phase of treatment or following a dose adjustment.


Q: How soon after starting Carvedilol Hexal do follow-up appointments usually happen?

The official titration protocol, especially for heart failure, requires that dose increases happen at intervals of no less than two weeks. This schedule necessitates monitoring of symptoms and vital signs before any increase is made.


Q: Is there a maximum official dose described for Carvedilol Hexal?

Yes, official regulatory documents specify a maximum recommended dose for different formulations of the medicine and for different conditions. This dose is based on established safety and efficacy data for each indication.


Q: What studies discuss the use of Carvedilol Hexal in pediatric patients?

Official documents state that the safety and efficacy in children and adolescents under 18 years of age have not been established. Therefore, its use is not permitted in this population.


Q: Do regulatory documents mention any risks of allergic reactions to Carvedilol Hexal?

Official documents list a history of serious hypersensitivity reactions to the medicine or its components as a contraindication, meaning an absolute exclusion from use. Symptoms of an allergic reaction may include rash or swelling.


Q: Is it normal to have cold hands and feet when taking Carvedilol Hexal?

Official documents list disturbances of peripheral circulation, including cold extremities, as a Common side effect. This is a known, documented effect related to how the medicine works on blood vessels.


Q: How is the safety of Carvedilol Hexal described for women who are pregnant or breastfeeding?

Use during pregnancy is restricted to cases where the potential benefit is judged to clearly outweigh any potential risk to the developing fetus. It is officially unknown if the medicine is excreted into human milk, leading to the recommendation to avoid breastfeeding or discontinue the medicine.


Q: What are the most common side effects people report when starting Carvedilol Hexal?

The most commonly documented adverse reactions are classified as Very Common, meaning they occur in 1 out of 10 people or more. These effects are officially listed as dizziness and fatigue, which are often more noticeable when treatment is first initiated.


Q: Is feeling dizzy a normal part of adjusting to Carvedilol Hexal?

Dizziness is documented as a Very Common side effect. Official safety information notes that this effect is often transient and can be more pronounced during the initial phase of treatment or following a change in dose.


Q: Can Carvedilol Hexal make you feel unusually tired?

Fatigue or lack of energy is documented as a Very Common side effect, meaning it is one of the most frequently reported effects. This is a known possibility listed in the official safety profiles.


Q: Can Carvedilol be crushed or split?

The preparation conditions depend on the specific formulation. Extended-release capsules must be swallowed whole and cannot be crushed or chewed. Immediate-release tablets, however, may be scored and divided for the purpose of dose adjustment as described in the administration guidelines.


Q: Can Carvedilol be taken with multivitamins or supplements?

Official interaction checks advise that multivitamins containing minerals may potentially decrease the effects of carvedilol. Separation of administration times, often by at least two hours, may be considered.

How should Carvedilol Hexal be stored and disposed of?

Official Storage and Handling

Carvedilol tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and should not be stored above 30 C. The product must be protected from environmental factors that can affect stability.

Storage Requirement Official Condition
Temperature Store between 20 C and 25 C (Do not store above 30 C)
Protection Keep dry; protect from light; keep from freezing
Packaging Keep in the original package; dispense in a tight, light-resistant container

All Carvedilol tablets and medication must be stored strictly out of the reach of children. The integrity of the packaging is required to maintain the labeled product shelf-life.

Official Disposal Rules

Expired or unused Carvedilol tablets must be safely thrown away in accordance with local requirements. The official instructions require preventing the product from reaching the sewage system or any water course.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carvedilol Hexal found in:

A-Z Index: